GlassScriptPhysician profile
Kyle J Alliman
NPI 1437360351
$7,508.98
in general payments reported to CMS, 2019-2025
18 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $288 · 2021: $950 · 2022: $1,136 · 2023: $413 · 2024: $1,047 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,083 · Travel and Lodging: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,082.88 |
| Travel and Lodging | $651.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $2,403.32 | 2019-2022 | |
| Onmark, INC. | $1,300.34 | 2025 | |
| Genentech, INC. | $1,093.53 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $905.92 | 2022-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $335.74 | 2021-2025 | Centurion, Constellation |
| Apellis Pharmaceuticals, INC. | $333.95 | 2023-2025 | Syfovre |
| Dutch Ophthalmic, USA | $279.30 | 2024 | Eva, Combined Machine, Tissueblue |
| Astellas Pharma US INC | $223.99 | 2024-2025 | Izervay |
| US Oncology Corporate, INC. | $222.10 | 2025 | |
| Abbvie INC. | $124.98 | 2025 | |
| Biogen, INC. | $121.73 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $90.83 | 2022-2023 | Xipere |
| Ani Pharmaceuticals, INC. | $25.81 | 2025 | Iluvien |
| Ocular Therapeutix, INC. | $20.85 | 2025 | Dextenza |
| Allergan, INC. | $14.10 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12.49 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$78,308.51 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Alliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.